Literature DB >> 10456395

European system for cardiac operative risk evaluation (EuroSCORE).

S A Nashef1, F Roques, P Michel, E Gauducheau, S Lemeshow, R Salamon.   

Abstract

OBJECTIVE: To construct a scoring system for the prediction of early mortality in cardiac surgical patients in Europe on the basis of objective risk factors.
METHODS: The EuroSCORE database was divided into developmental and validation subsets. In the former, risk factors deemed to be objective, credible, obtainable and difficult to falsify were weighted on the basis of regression analysis. An additive score of predicted mortality was constructed. Its calibration and discrimination characteristics were assessed in the validation dataset. Thresholds were defined to distinguish low, moderate and high risk groups.
RESULTS: The developmental dataset had 13,302 patients, calibration by Hosmer Lemeshow Chi square was (8) = 8.26 (P < 0.40) and discrimination by area under ROC curve was 0.79. The validation dataset had 1479 patients, calibration Chi square (10) = 7.5, P < 0.68 and the area under the ROC curve was 0.76. The scoring system identified three groups of risk factors with their weights (additive % predicted mortality) in brackets. Patient-related factors were age over 60 (one per 5 years or part thereof), female (1), chronic pulmonary disease (1), extracardiac arteriopathy (2), neurological dysfunction (2), previous cardiac surgery (3), serum creatinine >200 micromol/l (2), active endocarditis (3) and critical preoperative state (3). Cardiac factors were unstable angina on intravenous nitrates (2), reduced left ventricular ejection fraction (30-50%: 1, <30%: 3), recent (<90 days) myocardial infarction (2) and pulmonary systolic pressure >60 mmHg (2). Operation-related factors were emergency (2), other than isolated coronary surgery (2), thoracic aorta surgery (3) and surgery for postinfarct septal rupture (4). The scoring system was then applied to three risk groups. The low risk group (EuroSCORE 1-2) had 4529 patients with 36 deaths (0.8%), 95% confidence limits for observed mortality (0.56-1.10) and for expected mortality (1.27-1.29). The medium risk group (EuroSCORE 3-5) had 5977 patients with 182 deaths (3%), observed mortality (2.62-3.51), predicted (2.90-2.94). The high risk group (EuroSCORE 6 plus) had 4293 patients with 480 deaths (11.2%) observed mortality (10.25-12.16), predicted (10.93-11.54). Overall, there were 698 deaths in 14,799 patients (4.7%), observed mortality (4.37-5.06), predicted (4.72-4.95).
CONCLUSION: EuroSCORE is a simple, objective and up-to-date system for assessing heart surgery, soundly based on one of the largest, most complete and accurate databases in European cardiac surgical history. We recommend its widespread use.

Entities:  

Mesh:

Year:  1999        PMID: 10456395     DOI: 10.1016/s1010-7940(99)00134-7

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  523 in total

1.  The risk model of choice for coronary surgery in the UK.

Authors:  M Petrou; F Roques; L D Sharples; R Kinsman; B Keogh; F Carey; S A M Nashef
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

2.  Surgical performance measurement.

Authors:  Tom Treasure; Oswaldo Valencia; Chris Sherlaw-Johnson; Steve Gallivan
Journal:  Health Care Manag Sci       Date:  2002-11

3.  Association of Hospital Surgical Aortic Valve Replacement Quality With 30-Day and 1-Year Mortality After Transcatheter Aortic Valve Replacement.

Authors:  Harun Kundi; Jeffrey J Popma; Kamal R Khabbaz; Louis M Chu; Jordan B Strom; Linda R Valsdottir; Changyu Shen; Robert W Yeh
Journal:  JAMA Cardiol       Date:  2019-01-01       Impact factor: 14.676

4.  Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis.

Authors:  Nuria Vallejo Camazon; Lourdes Mateu; Germán Cediel; Laura Escolà-Vergé; Nuria Fernández-Hidalgo; Mercedes Gurgui Ferrer; Maria Teresa Perez Rodriguez; Guillermo Cuervo; Raquel Nuñez Aragón; Cinta Llibre; Nieves Sopena; Maria Dolores Quesada; Elisabeth Berastegui; Albert Teis; Jorge Lopez Ayerbe; Gladys Juncà; Francisco Gual; Elena Ferrer Sistach; Ainhoa Vivero; Esteban Reynaga; Maria Hernández Pérez; Christian Muñoz Guijosa; Lluisa Pedro-Botet; Antoni Bayés-Genís
Journal:  Cardiol J       Date:  2021-05-25       Impact factor: 2.737

5.  Validation of four different risk stratification systems in patients undergoing off-pump coronary artery bypass surgery: a UK multicentre analysis of 2223 patients.

Authors:  S Al-Ruzzeh; G Asimakopoulos; G Ambler; R Omar; R Hasan; B Fabri; A El-Gamel; A DeSouza; V Zamvar; S Griffin; D Keenan; U Trivedi; M Pullan; A Cale; M Cowen; K Taylor; M Amrani
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

6.  Risk prediction of cardiovascular surgery in Japanese patients.

Authors:  Takahiro Nishida; Munetaka Masuda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-09-14

7.  Validation of the JapanSCORE versus the logistic EuroSCORE for predicting operative mortality of cardiovascular surgery in Yamaguchi University Hospital.

Authors:  Hiroshi Kurazumi; Akihito Mikamo; Gaku Fukamitsu; Tomoaki Kudou; Masafumi Sato; Ryo Suzuki; Shigeru Ikenaga; Bungo Shirasawa; Kimikazu Hamano
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-09-14

8.  Mortality from isolated coronary bypass surgery: a comparison of the Society of Thoracic Surgeons and the EuroSCORE risk prediction algorithms.

Authors:  Irfan Qadir; Muhammad Musa Salick; Shazia Perveen; Hasanat Sharif
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-18

9.  Mortality data in adult cardiac surgery for named surgeons: retrospective examination of prospectively collected data on coronary artery surgery and aortic valve replacement.

Authors:  Ben Bridgewater
Journal:  BMJ       Date:  2005-03-05

10.  Strokes after cardiac surgery: mostly right hemispheric ischemic with mild residual damage.

Authors:  I Korn-Lubetzki; A Oren; E Asher; M Dano; D Bitran; D Fink; B Steiner-Birmanns
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.